Cowen analyst Yaron Werber assumed coverage of BeiGene with an Outperform rating and $170 price target. Werber believes Zanubrutinib and tislelizumab should be approved in the first half of 2019 in China, and sees several pivotal studies in other indications driving label expansion in 2020-2022. The analyst anticipates $1.2B in global sales for Zanubrutinib.
https://thefly.com/landingPageNews.php?id=2869887
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.